A Non-interventional Study of Remazolam Methyl Benzene Sulfonic Acid for Injection in Real-world Clinical Practice

Hengrui Medicine

Status: Completed

Conditions: Gastroscopic and Colonoscopic Sedation

Treatments: Drug: Remimazolam Tosilate for Injection

Study type: Observational

Funder types: Industry

Identifiers

NCT05254366

ARMS

Details and patient eligibility

About

This is a non-interventional study of remazolam toluenesulfonate (rebenin ®) for injection in Chinese patients. A total of 2000 patients were enrolled in this study based on the preliminary safety assessment of rebenin ®, and all safety information was obtained

Enrollment: 2,022 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Use rebenin ® for painless gastroscopic sedation and painless colonoscopic sedation
2. Patients need to sign informed consent

Exclusion criteria

1. Patients who are participating in or planning to participate in any interventional clinical trial
2. The investigator considers that there are any other reasons for the patient's ineligibility for the study

Trial design

2,022 participants in 2 patient groups

Cohort 1

Description:

Painless gastroscopic sedation cohort

Treatment:

Drug: Remimazolam Tosilate for Injection

Cohort 2

Description:

Painless colonoscopy sedation cohort

Treatment:

Drug: Remimazolam Tosilate for Injection